...
首页> 外文期刊>Annals of allergy, asthma, and immunology >Allergen immunotherapy in a patient with human immunodeficiency virus: effect on T-cell activation and viral replication.
【24h】

Allergen immunotherapy in a patient with human immunodeficiency virus: effect on T-cell activation and viral replication.

机译:人类免疫缺陷病毒患者的变应原免疫疗法:对T细胞活化和病毒复制的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Allergen immunotherapy is a major therapeutic modality in the treatment of allergic rhinitis. However, with T-cell activation potential, its role in patients with human immunodeficiency virus (HIV) was theoretically limited. OBJECTIVE: To report the results of allergen immunotherapy in a patient with HIV treated with highly active antiretroviral therapy (HAART). METHODS: A 44-year-old man with a history of HIV did not respond to medical therapy for allergic rhinitis. His HIV status was well controlled with HAART. Owing to the severity of his allergic rhinitis symptoms, he accepted the risk of allergy immunotherapy despite the unknown effect of immunotherapy in patients with HIV. RESULTS: After 6 weeks of weekly immunotherapy injections, his viral load remained undetectable and his CD4 cell count changed from 540 to 570 cells/microL. After 16 weeks of weekly immunotherapy, his viral load increased to 10,900 copies/mL, and his CD4 cell count increased to 665 cells/microL. After 24 weeks of weekly immunotherapy, his viral load returned to an undetectable level, and his CD4 cell count stabilized at 356 cells/microL. Despite his notable change in HIV status, he continues to receive the same HAART. He currently continues en route to maintenance immunotherapy. CONCLUSIONS: The effect of allergen immunotherapy on HIV infection has not been previously reported. A concern remains that any form of immunotherapy may negatively affect HIV disease progression. This case illustrates that weekly allergen immunotherapy may have induced limited T-cell proliferation and a modest increase in RNA viral load, which resolved with continuation of HAART.
机译:背景:过敏原免疫疗法是过敏性鼻炎的主要治疗方式。但是,由于具有T细胞活化的潜力,其在人类免疫缺陷病毒(HIV)患者中的作用在理论上受到限制。目的:报道高活性抗逆转录病毒疗法(HAART)治疗的艾滋病毒患者的过敏原免疫疗法的结果。方法:一名44岁的艾滋病毒感染者对过敏性鼻炎的药物治疗没有反应。 HAART可以很好地控制他的艾滋病毒状况。由于他的过敏性鼻炎症状的严重性,尽管免疫疗法在HIV患者中的作用尚不清楚,但他还是接受了过敏免疫疗法的风险。结果:每周注射免疫疗法6周后,仍然无法检测到他的病毒载量,并且他的CD4细胞计数从540细胞/微升改变为570细胞/微升。每周免疫治疗16周后,他的病毒载量增加到10900拷贝/ mL,他的CD4细胞计数增加到665细胞/微升。每周免疫治疗24周后,他的病毒载量恢复到无法检测的水平,并且他的CD4细胞计数稳定在356个细胞/微升。尽管他的艾滋病毒感染状况发生了显着变化,但他仍继续接受同样的HAART。他目前正在继续进行免疫治疗。结论:过敏原免疫疗法对HIV感染的影响尚未见报道。人们仍然担心,任何形式的免疫疗法都可能对HIV疾病的发展产生负面影响。这种情况说明,每周的过敏原免疫疗法可能诱导了有限的T细胞增殖和RNA病毒载量的适度增加,这一点随着HAART的持续治疗而得以解决。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号